Furthermore, the value of high TMB as a favourable biomarker of immunotherapy response and survival has been noted across PD-L1 expression levels and has been able to independently predict outcomes irrespective of microsatellite instability (MSI) status or underlying tumour type (60, 61). This evidence concerns the gene CD274 and neoplasm.